<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00790127</url>
  </required_header>
  <id_info>
    <org_study_id>HQP-2008-003b</org_study_id>
    <nct_id>NCT00790127</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia</brief_title>
  <official_title>A Multi-National, Blinded, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HQK-1001 in Subjects With Beta Thalassemia Intermedia, Including Hemoglobin E Beta Thalassemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HemaQuest Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HemaQuest Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of HQK-1001 administered
      daily for 8 weeks in subjects with beta thalassemia intermedia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by (1) adverse events, (2) laboratory values (3) vital signs (4) physical exam</measure>
    <time_frame>168 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics assessed by plasma drug concentration levels</measure>
    <time_frame>140 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics assessed by red blood cell production and induction of fetal hemoglobin</measure>
    <time_frame>168 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Beta Thalassemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HQK-1001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HQK-1001</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HQK-1001</intervention_name>
    <description>HQK-1001 capsules (10, 20, 30 or 40 mg) administered once a day, orally, for 56 days</description>
    <arm_group_label>HQK-1001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo capsules administered once a day, orally, for 56 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of beta thalassemia intermedia or hemoglobin E beta thalassemia

          -  Average of the initial two hemoglobin levels of less than 10 g/dL within ≥ 30 days
             prior to randomization.

          -  Age ≥ 12 and ≤ 60 years

          -  Able and willing to give informed consent or assent (if less than 18 years of age) and
             comply with all study procedures

          -  If female and of childbearing potential, must have a documented negative pregnancy
             test at Day -1 and must agree to use one or more locally medically accepted methods of
             contraception in the month prior to randomization, through the entire study, and for 4
             weeks after the last dosing of study medication

        Exclusion Criteria:

          -  Spleen palpable ≥ 2 cm below the left costal margin

          -  Pulmonary hypertension requiring oxygen therapy

          -  QTc &gt; 450 msec on screening ECG

          -  Infection with hepatitis C, hepatitis B requiring therapy

          -  Known infection with HIV

          -  Red blood cell (RBC) transfusions within 2 months prior to administration of study
             medication with stable hemoglobin levels

          -  Fever greater than 38.5°C in the week prior to administration of study medication

          -  ALT &gt; 4x upper limit of normal (ULN)

          -  Baseline elevation of CPK value prior to randomization

          -  Treatment with hydroxyurea within 2 months prior to administration of study medication

          -  Cancer diagnosis within 5 years of randomization (except for non-melanoma cutaneous
             malignancies)

          -  Serum creatinine &gt; 1.5 mg/dl

          -  Received investigational systemic therapy within 30 days prior to randomization

          -  Currently pregnant or breast feeding a child

          -  Subject history of clinically significant arrhythmias or syncope

          -  Known current drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noppadol Siritanaratkul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Siriraj Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chronic Care Center</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <state>Bangkoknoin District</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lebanon</country>
    <country>Thailand</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2008</study_first_submitted>
  <study_first_submitted_qc>November 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <disposition_first_submitted>May 13, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>May 13, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 18, 2011</disposition_first_posted>
  <last_update_submitted>May 18, 2011</last_update_submitted>
  <last_update_submitted_qc>May 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Susan Perrine, M.D. Chief Scientific Officer, VP Clinical Affairs</name_title>
    <organization>HemaQuest Pharmaceuticals Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

